Sotac Pharmaceuticals

Sotac Pharmaceuticals Liabilities

The The Liabilities of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 21, 2026 is 710.76 M INR. In the previous year, The Liabilities was 601.00 M INR — a change of 18.26% (higher).

Liabilities

710.76 MINR

YoY

18.26%

Last updated:

In 2025, Sotac Pharmaceuticals's total liabilities amounted to 710.76 M INR, a 18.26% difference from the 601.00 M INR total liabilities in the previous year.

The Sotac Pharmaceuticals Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2020
273.25 M INR
Jan 1, 2021
322.04 M INR
Jan 1, 2022
286.32 M INR
Jan 1, 2024
601.00 M INR
Jan 1, 2025
710.76 M INR
The Sotac Pharmaceuticals Liabilities history
YEARLiabilitiesYoY
710.76 MINR+18.26%
601.00 MINR+109.91%
286.32 MINR-11.09%
322.04 MINR+17.86%
273.25 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Sotac Pharmaceuticals's Liabilities

Sotac Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Sotac Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Sotac Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Sotac Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Sotac Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Sotac Pharmaceuticals stock

The Liabilities of Sotac Pharmaceuticals is 710.76 M INR in 2025.

The Liabilities of Sotac Pharmaceuticals changed from 601.00 M INR to 710.76 M INR, representing a 18.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Sotac Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Sotac Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sotac Pharmaceuticals